Hcw biologics reports second quarter 2022 financial results and recent business highlights

Miramar, fla., aug. 12, 2022 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended june 30, 2022.
HCWB Ratings Summary
HCWB Quant Ranking